Insight Molecular Diagnostics Price to Sales Ratio 2014-2025 | IMDX
Historical PS ratio values for Insight Molecular Diagnostics (IMDX) over the last 10 years. The current P/S ratio for Insight Molecular Diagnostics as of June 27, 2025 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Insight Molecular Diagnostics P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2025-06-27 | 3.20 | 15.00 | |
| 2025-03-31 | 3.06 | $0.21 | 14.34 |
| 2024-12-31 | 2.38 | $0.15 | 15.71 |
| 2024-09-30 | 2.85 | $0.08 | 36.17 |
| 2024-06-30 | 2.95 | $0.12 | 24.11 |
| 2024-03-31 | 2.93 | $0.17 | 17.08 |
| 2023-12-31 | 2.50 | $0.20 | 12.50 |
| 2023-09-30 | 3.12 | $0.21 | 14.97 |
| 2023-06-30 | 4.60 | $0.17 | 27.41 |
| 2023-03-31 | 7.08 | $0.15 | 46.43 |
| 2022-12-31 | 6.42 | $0.19 | 34.69 |
| 2022-09-30 | 14.60 | $-0.30 | 0.00 |
| 2022-06-30 | 18.00 | $-0.10 | 0.00 |
| 2022-03-31 | 29.80 | $0.31 | 95.04 |
| 2021-12-31 | 43.40 | $0.50 | 85.96 |
| 2021-09-30 | 71.20 | $1.09 | 65.05 |
| 2021-06-30 | 114.80 | $1.04 | 109.91 |
| 2021-03-31 | 103.80 | $0.64 | 163.32 |
| 2020-12-31 | 47.80 | $0.37 | 130.23 |
| 2020-09-30 | 27.80 | $0.21 | 130.08 |
| 2020-06-30 | 38.20 | $0.05 | 785.21 |
| 2020-03-31 | 49.00 | $0.01 | 0.00 |
| 2019-12-31 | 45.00 | 0 | 0.00 |
| 2019-09-30 | 42.00 | 0 | 0.00 |
| 2019-06-30 | 49.80 | 0 | 0.00 |
| 2019-03-31 | 79.00 | 0 | 0.00 |
| 2018-12-31 | 27.60 | 0 | 0.00 |
| 2018-09-30 | 50.00 | 0 | 0.00 |
| 2018-06-30 | 51.00 | 0 | 0.00 |
| 2018-03-31 | 42.00 | 0 | 0.00 |
| 2017-12-31 | 93.00 | 0 | 0.00 |
| 2017-09-30 | 151.00 | 0 | 0.00 |
| 2017-06-30 | 104.00 | 0 | 0.00 |
| 2017-03-31 | 119.00 | 0 | 0.00 |
| 2016-12-31 | 141.00 | 0 | 0.00 |
| 2016-09-30 | 100.80 | 0 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.092B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.313B | 58.92 |
| Tempus AI (TEM) | United States | $11.516B | 0.00 |
| Doximity (DOCS) | United States | $11.474B | 53.12 |
| Hims & Hers Health (HIMS) | United States | $11.060B | 114.91 |
| IRhythm Technologies (IRTC) | United States | $4.939B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.905B | 61.02 |
| Hinge Health (HNGE) | United States | $3.629B | 0.00 |
| Privia Health (PRVA) | United States | $2.682B | 183.33 |
| Enovis (ENOV) | United States | $1.815B | 10.12 |
| Phreesia (PHR) | United States | $1.695B | 0.00 |
| Schrodinger (SDGR) | United States | $1.512B | 0.00 |
| 10x Genomics (TXG) | United States | $1.444B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.405B | 0.00 |
| Azenta (AZTA) | United States | $1.400B | 65.08 |
| Omnicell (OMCL) | United States | $1.376B | 24.28 |
| Evolent Health (EVH) | United States | $1.310B | 111.60 |
| Claritev (CTEV) | United States | $0.716B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.599B | 0.00 |
| Veradigm (MDRX) | United States | $0.498B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.485B | 0.00 |
| Talkspace (TALK) | United States | $0.463B | 138.50 |
| Standard BioTools (LAB) | United States | $0.452B | 0.00 |
| TruBridge (TBRG) | United States | $0.349B | 773.33 |
| Outset Medical (OM) | United States | $0.338B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.265B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.254B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.206B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.167B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.127B | 0.00 |
| American Well (AMWL) | United States | $0.124B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.109B | 0.00 |
| Pulmonx (LUNG) | United States | $0.105B | 0.00 |
| CareCloud (CCLD) | United States | $0.102B | 3.89 |
| 111 (YI) | China | $0.060B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.051B | 0.00 |
| HeartBeam (BEAT) | United States | $0.046B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.046B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.037B | 0.00 |
| Zhongchao (ZCMD) | China | $0.029B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.014B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.010B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.009B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |